Clinical Trial

A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main objective of this trial is to evaluate the effects of verducatib in the range of therapeutic to supra-therapeutic exposures on the QT/QTc-interval and other ECG parameters
Trial Details
NCT Number NCT07760246
Lead Sponsor Boehringer Ingelheim
Conditions Healthy
Enrollment 56 participants
Start Date 2026-08-17
Primary Completion 2026-12-16 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-12